Get the Stockscreener App
4.195
4.37%
-0.155
Anixa Biosciences Inc stock is traded at $4.195, with a volume of 38,590.
It is down -4.37% in the last 24 hours and up +0.48% over the past month.
Anixa Biosciences Inc a cancer-focused biotechnology company, develops vaccines and therapies that are focused on critical unmet needs in oncology. The company is developing both diagnostics and therapeutics to detect cancer early, which is curable, and to treat those afflicted once diagnosed. Its segment includes CAR-T Therapeutics; Cancer Vaccines; Anti-Viral Therapeutics and others.
See More
Previous Close:
$4.35
Open:
$4.35
24h Volume:
38,590
Relative Volume:
0.21
Market Cap:
$138.09M
Revenue:
-
Net Income/Loss:
$-12.48M
P/E Ratio:
-10.76
EPS:
-0.39
Net Cash Flow:
$-7.93M
1W Performance:
+1.46%
1M Performance:
+0.48%
6M Performance:
+66.40%
1Y Performance:
+29.19%
1-Day Range:
$4.1511
$4.38
1-Week Range:
$4.0865
$4.59
52-Week Range:
$2.07
$4.98
Anixa Biosciences Inc Stock (ANIX) Company Profile
Name
Anixa Biosciences Inc
Sector
Industry
Phone
408-708-9808
Address
3150 ALMADEN EXPRESSWAY, SUITE 250, SAN JOSE
Compare ANIX with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ANIX
Anixa Biosciences Inc
|
4.195 | 143.19M | 0 | -12.48M | -7.93M | -0.39 |
|
VRTX
Vertex Pharmaceuticals Inc
|
427.20 | 107.58B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
775.57 | 80.03B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
432.16 | 57.37B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
903.14 | 55.83B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
206.66 | 44.13B | 447.02M | -1.18B | -906.14M | -6.1812 |
Anixa Biosciences Inc Stock (ANIX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Mar-21-25 | Initiated | Maxim Group | Buy |
| Dec-23-22 | Initiated | Chardan Capital Markets | Buy |
| Apr-12-21 | Initiated | H.C. Wainwright | Buy |
Anixa Biosciences Inc Stock (ANIX) Latest News
Anixa Biosciences Announces World Health Organization (WHO) Approval of International Non-Proprietary Name for its CAR-T Therapy, Marking a Key Milestone Toward Global Recognition and Future Commercialization - Quantisnow
Anixa Biosciences (NASDAQ:ANIX) Stock Rating Lowered by Zacks Research - MarketBeat
Is Anixa Biosciences Inc. stock a top momentum playGold Moves & Precise Entry and Exit Recommendations - newser.com
Can Anixa Biosciences Inc. (CY71) stock sustain double digit ROEWeekly Loss Report & Weekly Watchlist of Top Performers - newser.com
How geopolitical risks impact Anixa Biosciences Inc. (CY71) stockWeekly Trade Recap & High Return Trade Guides - newser.com
Why Anixa Biosciences Inc. stock is recommended by analysts2025 Risk Factors & Long-Term Growth Portfolio Plans - newser.com
How risky is Anixa Biosciences Inc. (CY71) stock compared to peersM&A Rumor & Fast Entry High Yield Stock Tips - newser.com
Intraday pattern recognizer results for Anixa Biosciences Inc.July 2025 EndofMonth & Reliable Price Breakout Alerts - newser.com
Anixa Biosciences Inc. stock prediction for this week2025 Bull vs Bear & Daily Volume Surge Signals - newser.com
Can Anixa Biosciences Inc. (CY71) stock resist broad market declinesPortfolio Value Summary & Real-Time Stock Entry Alerts - newser.com
Will Anixa Biosciences Inc. stock benefit from commodity pricesWeekly Trend Recap & Consistent Profit Alerts - newser.com
Backtesting results for Anixa Biosciences Inc. trading strategies2025 Key Lessons & Breakout Confirmation Alerts - newser.com
Can Anixa Biosciences Inc. (CY71) stock sustain revenue momentumJuly 2025 Intraday Action & AI Enhanced Execution Alerts - newser.com
Will Anixa Biosciences Inc. (CY71) stock outperform foreign stocksPortfolio Profit Report & Fast Moving Stock Watchlists - newser.com
What momentum indicators show for Anixa Biosciences Inc. stock - newser.com
Anixa Biosciences Inc (NASDAQ:ANIX) Receives $9.00 Average PT from Analysts - Defense World
Will Anixa Biosciences Inc. stock maintain growth storyFed Meeting & Accurate Entry/Exit Alerts - newser.com
Anixa Biosciences (ANIX) Price Target Increased by 11.11% to 10.20 - Nasdaq
WHO approves name for Anixa’s ovarian cancer CAR-T therapy By Investing.com - Investing.com Nigeria
How Anixa Biosciences Inc. stock reacts to oil pricesRate Hike & AI Powered Buy and Sell Recommendations - newser.com
Anixa Biosciences (ANIX) Unveils New Name for Ovarian Cancer The - GuruFocus
WHO approves name for Anixa’s ovarian cancer CAR-T therapy - Investing.com
Anixa Biosciences Inc Stock (ANIX) Financials Data
Revenue
Net Income
Cash Flow
EPS
Anixa Biosciences Inc Stock (ANIX) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Titterton Lewis H jr | Director |
Jul 31 '25 |
Buy |
3.08 |
10,000 |
30,800 |
953,334 |
| KUMAR AMIT | Chief Executive Officer |
Jul 30 '25 |
Buy |
3.16 |
5,000 |
15,800 |
579,925 |
| Baskies Arnold M | Director |
Jul 18 '25 |
Buy |
3.39 |
5,000 |
16,950 |
125,000 |
| Titterton Lewis H jr | Director |
Jul 11 '25 |
Buy |
3.14 |
10,000 |
31,400 |
943,334 |
| KUMAR AMIT | Chief Executive Officer |
Jul 11 '25 |
Buy |
3.15 |
5,000 |
15,750 |
574,925 |
| KUMAR AMIT | Chief Executive Officer |
Jun 04 '25 |
Buy |
2.85 |
10,000 |
28,500 |
569,925 |
| Baskies Arnold M | Director |
Jan 28 '25 |
Buy |
2.82 |
5,000 |
14,100 |
120,000 |
| Titterton Lewis H jr | Director |
Jan 23 '25 |
Buy |
2.91 |
2,000 |
5,820 |
932,334 |
| Titterton Lewis H jr | Director |
Jan 24 '25 |
Buy |
3.00 |
1,000 |
3,000 |
933,334 |
| Titterton Lewis H jr | Director |
Jan 22 '25 |
Buy |
3.01 |
2,000 |
6,020 |
930,334 |
0.07%
0.84%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):